Ubiquitin-proteasome-system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF.
Atrophy
Diastolic heart failure
Heart failure
Mitochondria
Skeletal muscle exercise
Ubiquitin-proteasome system genetics
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
17
03
2021
received:
05
08
2020
accepted:
22
04
2021
pubmed:
7
5
2021
medline:
29
10
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Skeletal muscle (SM) alterations contribute to exercise intolerance in heart failure patients with preserved (HFpEF) or reduced (HFrEF) left ventricular ejection fraction (LVEF). Protein degradation via the ubiquitin-proteasome-system (UPS), nuclear apoptosis, and reduced mitochondrial energy supply is associated with SM weakness in HFrEF. These mechanisms are incompletely studied in HFpEF, and a direct comparison between these groups is missing. Patients with HFpEF (LVEF ≥ 50%, septal E/e' > 15 or >8 and NT-proBNP > 220 pg/mL, n = 20), HFrEF (LVEF ≤ 35%, n = 20) and sedentary control subjects (Con, n = 12) were studied. Inflammatory markers were measured in serum, and markers of the UPS, nuclear apoptosis, and energy metabolism were determined in percutaneous SM biopsies. Both HFpEF and HFrEF showed increased proteolysis (MuRF-1 protein expression, ubiquitination, and proteasome activity) with proteasome activity significantly related to interleukin-6. Proteolysis was more pronounced in patients with lower exercise capacity as indicated by peak oxygen uptake in per cent predicted below the median. Markers of apoptosis did not differ between groups. Mitochondrial energy supply was reduced in HFpEF and HFrEF (complex-I activity: -31% and -53%; malate dehydrogenase activity: -20% and -29%; both P < 0.05 vs. Con). In contrast, short-term energy supply via creatine kinase was increased in HFpEF but decreased in HFrEF (47% and -45%; P < 0.05 vs. Con). Similarly to HFrEF, skeletal muscle in HFpEF is characterized by increased proteolysis linked to systemic inflammation and reduced exercise capacity. Energy metabolism is disturbed in both groups; however, its regulation seems to be severity-dependent.
Sections du résumé
BACKGROUND
Skeletal muscle (SM) alterations contribute to exercise intolerance in heart failure patients with preserved (HFpEF) or reduced (HFrEF) left ventricular ejection fraction (LVEF). Protein degradation via the ubiquitin-proteasome-system (UPS), nuclear apoptosis, and reduced mitochondrial energy supply is associated with SM weakness in HFrEF. These mechanisms are incompletely studied in HFpEF, and a direct comparison between these groups is missing.
METHODS AND RESULTS
Patients with HFpEF (LVEF ≥ 50%, septal E/e' > 15 or >8 and NT-proBNP > 220 pg/mL, n = 20), HFrEF (LVEF ≤ 35%, n = 20) and sedentary control subjects (Con, n = 12) were studied. Inflammatory markers were measured in serum, and markers of the UPS, nuclear apoptosis, and energy metabolism were determined in percutaneous SM biopsies. Both HFpEF and HFrEF showed increased proteolysis (MuRF-1 protein expression, ubiquitination, and proteasome activity) with proteasome activity significantly related to interleukin-6. Proteolysis was more pronounced in patients with lower exercise capacity as indicated by peak oxygen uptake in per cent predicted below the median. Markers of apoptosis did not differ between groups. Mitochondrial energy supply was reduced in HFpEF and HFrEF (complex-I activity: -31% and -53%; malate dehydrogenase activity: -20% and -29%; both P < 0.05 vs. Con). In contrast, short-term energy supply via creatine kinase was increased in HFpEF but decreased in HFrEF (47% and -45%; P < 0.05 vs. Con).
CONCLUSIONS
Similarly to HFrEF, skeletal muscle in HFpEF is characterized by increased proteolysis linked to systemic inflammation and reduced exercise capacity. Energy metabolism is disturbed in both groups; however, its regulation seems to be severity-dependent.
Identifiants
pubmed: 33955206
doi: 10.1002/ehf2.13405
pmc: PMC8318515
doi:
Substances chimiques
Ubiquitin
0
Proteasome Endopeptidase Complex
EC 3.4.25.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2556-2568Informations de copyright
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Circ Heart Fail. 2016 Sep;9(9):
pubmed: 27609832
Eur Heart J. 2012 Dec;33(23):2917-27
pubmed: 22952138
Circulation. 1989 Nov;80(5):1338-46
pubmed: 2805270
Endocrinology. 2001 Apr;142(4):1489-96
pubmed: 11250929
JACC Heart Fail. 2016 Aug;4(8):636-45
pubmed: 27179829
Curr Med Chem. 2009;16(10):1266-77
pubmed: 19355884
World J Transplant. 2013 Dec 24;3(4):78-90
pubmed: 24392312
Mol Cell Biochem. 1999 Nov;201(1-2):33-40
pubmed: 10630620
Circulation. 2012 Jun 5;125(22):2716-27
pubmed: 22565934
ESC Heart Fail. 2021 Aug;8(4):2556-2568
pubmed: 33955206
Heart. 2000 Oct;84(4):431-7
pubmed: 10995417
Eur J Heart Fail. 2020 Mar;22(3):391-412
pubmed: 32133741
Am J Physiol Heart Circ Physiol. 2014 May;306(9):H1364-70
pubmed: 24658015
Science. 1997 Feb 21;275(5303):1132-6
pubmed: 9027315
Am J Cardiol. 1983 Jan 1;51(1):177-82
pubmed: 6849256
Curr Heart Fail Rep. 2017 Dec;14(6):489-497
pubmed: 28940089
Eur Heart J. 2013 Feb;34(7):512-9
pubmed: 23178647
Scand J Clin Lab Invest. 1975 Nov;35(7):609-16
pubmed: 1108172
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Circ Heart Fail. 2009 Mar;2(2):113-20
pubmed: 19808326
Int J Cardiol. 2016 Nov 1;222:41-46
pubmed: 27454614
Int J Cardiol. 2013 Aug 10;167(3):975-80
pubmed: 22445192
J Am Coll Cardiol. 1999 Mar 15;33(4):959-65
pubmed: 10091822
Am J Cardiol. 2014 Apr 1;113(7):1211-6
pubmed: 24507172
Circulation. 2017 Feb 28;135(9):839-849
pubmed: 28082387
Heart Fail Rev. 2020 Mar 26;:
pubmed: 32219614
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):939-953
pubmed: 28887874
Circulation. 1990 Feb;81(2):518-27
pubmed: 2297859
Circ Heart Fail. 2017 Jul;10(7):
pubmed: 28705910
J Am Soc Nephrol. 2009 Mar;20(3):604-12
pubmed: 19158350
J Am Coll Cardiol. 2001 Oct;38(4):947-54
pubmed: 11583863
Am J Physiol Regul Integr Comp Physiol. 2005 May;288(5):R1288-96
pubmed: 15650125
Eur J Prev Cardiol. 2014 Nov;21(2 Suppl):18-25
pubmed: 25354950
J Physiol. 2014 Sep 1;592(17):3767-82
pubmed: 24951621
Nat Clin Pract Cardiovasc Med. 2008 Jul;5(7):375-86
pubmed: 18542106
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
J Card Fail. 2014 Jun;20(6):422-30
pubmed: 24704539
J Am Coll Cardiol. 1999 Jan;33(1):174-9
pubmed: 9935026